These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 6415754)

  • 1. Tyramine and depressive illness.
    Psychopharmacol Bull; 1983; 19(3):496-504. PubMed ID: 6415754
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].
    Deverina IS
    Biokhimiia; 1980 Oct; 45(10):1897-908. PubMed ID: 6786369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyramine conjugation deficit in migraine, tension-type headache, and depression.
    Merikangas KR; Stevens DE; Merikangas JR; Katz CB; Glover V; Cooper T; Sandler M
    Biol Psychiatry; 1995 Dec; 38(11):730-6. PubMed ID: 8580225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High positive correlation between urinary free tyramine excretion rate and "whole body" norepinephrine turnover in depressed patients.
    Linnoila M; Karoum F; Potter WZ
    Biol Psychiatry; 1982 Sep; 17(9):1031-6. PubMed ID: 7138992
    [No Abstract]   [Full Text] [Related]  

  • 5. Alterations in noradrenergic function during clorgyline treatment.
    Pickar D; Lake CR; Cohen RM; Jimerson DC; Murphy DL
    Commun Psychopharmacol; 1980; 4(5):379-86. PubMed ID: 7333093
    [No Abstract]   [Full Text] [Related]  

  • 6. Tyramine conjugation as a marker for depressive illness.
    Lancet; 1984 Oct; 2(8409):963. PubMed ID: 6149348
    [No Abstract]   [Full Text] [Related]  

  • 7. D-amphetamine and DL-alpha-N-methyltryptamine eliminate the irreversible inhibition of mitochondrial monoamine oxidase, caused by clorgyline. The specific action on the tyramine oxidation.
    Severina IS
    Biochem Int; 1984 Aug; 9(2):219-28. PubMed ID: 6487343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity].
    Severina IS; Klimova GI; Nersisian AA
    Biokhimiia; 1981 Nov; 46(11):2043-55. PubMed ID: 6797482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
    Barbelivien A; Nyman L; Haapalinna A; Sirviö J
    Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyramine conjugation test as a trait marker for endogenous unipolar depression and a predictor of treatment response.
    Jarman J
    Mol Aspects Med; 1992; 13(3):249-61. PubMed ID: 1435105
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyramine sulfoconjugation in relation to depression in migraine. A pilot study.
    Sandler M; Jarman J; Fernandez M; Glover V; Davies PT; Thompson C; Rose FC
    Clin J Pain; 1989; 5(1):19-21. PubMed ID: 2520380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition.
    Marcocci L; De Marchi U; Salvi M; Milella ZG; Nocera S; Agostinelli E; Mondovi B; Toninello A
    J Membr Biol; 2002 Jul; 188(1):23-31. PubMed ID: 12172644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyramine metabolism and migraine: a metabolic defect.
    Mullen PE; Smith I
    Br J Pharmacol; 1971 Feb; 41(2):413P-414P. PubMed ID: 5572308
    [No Abstract]   [Full Text] [Related]  

  • 16. Decreased urinary output of conjugated tyramine is associated with lifetime vulnerability to depressive illness.
    Carter SM; Reveley MA; Sandler M; Dewhurst J; Little BC; Hayworth J; Priest RG
    Psychiatry Res; 1980 Sep; 3(1):13-21. PubMed ID: 6934553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on urinary phenolic compounds in man. 3. excretion of o-tyramine.
    Nishimura T; Gjessing LR
    Scand J Clin Lab Invest; 1966; 18(2):217-20. PubMed ID: 5914747
    [No Abstract]   [Full Text] [Related]  

  • 19. Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline.
    Sharma U; Roberts ES; Hollenberg PF
    Drug Metab Dispos; 1996 Jun; 24(6):669-75. PubMed ID: 8781784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyramine metabolism. A method for the quantitative extraction of radioactive tyramine and its metabolites from urine.
    Smith I; March SE
    Clin Chim Acta; 1972 Sep; 40(2):415-9. PubMed ID: 5056141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.